Employees: 489
Size Beijing Science Sun Pharmaceutical (300485.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $517M, the 3619th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.25 on 18 Nov 2026.
Performance Over six months the shares fell 28.6%, against -16.0% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 19 in its peer set.
Growth Revenue fell 10.6% over the last twelve months (peer median +11.6%); the operating margin is -8.2% (peer median 11.2%).
Valuation It trades at 5.6× enterprise value to sales against a peer median of 3.9× (7th most expensive of 19).
Capital Return on invested capital runs 6.1 points below its cost of capital (6.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥359M | CN¥401M | CN¥415M | CN¥474M | CN¥730M |
| Revenue growth | — | -3% | -13% | -35% | — |
| Gross profit | CN¥255M | CN¥244M | CN¥258M | CN¥317M | CN¥542M |
| EBITDA | n/a | CN¥30.1M | CN¥69.9M | CN¥8.45M | CN¥71.4M |
| Net income | -CN¥167M | CN¥14.6M | -CN¥68.9M | CN¥103M | CN¥205M |
| Free cash flow | -CN¥52.1M | -CN¥30.9M | CN¥60.1M | -CN¥16.1M | CN¥107M |
| Capital expenditure | CN¥90.7M | CN¥100M | CN¥101M | CN¥52.9M | CN¥43.3M |
| Total debt | CN¥29.0M | CN¥19.7M | CN¥0 | CN¥0 | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300485.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.0% | -7.0% | 10th lowest of 20 |
| 6-month return | -28.6% | -16.0% | 3rd lowest of 19 |
| Distance from 52-week high | -47.5% | -38.7% | 4th lowest of 20 |
| Revenue growth (TTM) | -10.6% | +11.6% | 2nd lowest of 19 |
| Operating margin | -8.2% | 11.2% | 5th lowest of 19 |
| EV / Sales | 5.6× | 3.9× | 7th most expensive of 19 |
| ROIC minus cost of capital | -6.1 pp | -2.7 pp | 5th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | 5.6× | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | 16.2× | 49.3% | -1.5% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 5.5× | 28.2% | +15.8% |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | 0.7× | 2.4% | +5.0% |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | 6.6× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | 2.5× | 16.7% | +4.4% |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 7.4× | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | 11.0× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | 2.2× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |